SCHEMBL22801262

SCHEMBL22801262

CCCCCCCO[PH]1(O)OC[C@H]2O[C@@H](n3cc(F)c(=O)[nH]c3=O)C[C@@H]2O1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ PLA2G1B P04054 1/20 0.39
▸ ATG4B Q9Y4P1 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ TK2 O00142 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ MAPK3 P27361 1/20 0.37
▸ ASAH1 Q13510 1/20 0.37
▸ SQOR Q9Y6N5 1/20 0.37
▸ TK1 P04183 2/20 0.37
▸ DHFR P00374 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ PMP22 Q01453 1/20 0.36
▸ HBB P68871 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21178589 1.00 LMNA (0.45) LMNASMN1; SMN2PLA2G1BATG4BMAPT
SCHEMBL22801209 1.00 LMNA (0.45) LMNASMN1; SMN2PLA2G1BATG4BMAPT
SCHEMBL21179131 1.00 LMNA (0.45) LMNASMN1; SMN2PLA2G1BATG4BMAPT
SCHEMBL21178038 0.99 LMNA (0.45) LMNASMN1; SMN2PLA2G1BATG4BMAPT
SCHEMBL22801236 0.93 LMNA (0.47) LMNASMN1; SMN2MAPTESR1TK2
SCHEMBL22801221 0.90 LMNA (0.43) LMNASMN1; SMN2MAPTESR1TK1
SCHEMBL22589438 0.90 TK1 (0.48) TK2TK1DHFR
SCHEMBL22801182 0.88 SMN1; SMN2 (0.41) LMNASMN1; SMN2PLA2G1BATG4BMAPT
SCHEMBL22801218 0.86 LMNA (0.43) LMNASMN1; SMN2MAPTESR1TK2
SCHEMBL21178133 0.84 LMNA (0.45) LMNASMN1; SMN2MAPTESR1TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206896-B Cyclic deoxyribonucleotide compounds 纽科利制药公司 2024-12-17 — — CN disclosed
US-12110311-B2 Cyclic deoxyribonucleotide compounds NUCORION PHARMACEUTICALS, INC. (US) 2024-10-08 — — US disclosed
US-20220298199-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2022-09-22 — — US disclosed
US-11427550-B2 5-fluorouracil compounds NUCORION PHARMACEUTICALS, INC. (US) 2022-08-30 — — US disclosed
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298199-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS DPYD, TYMP, TYMS LMNA 1892/4885SMN1; SMN2 2792/4885PLA2G1B 2398/4885
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS DPYD, DHFR, FAU LMNA 1225/4885SMN1; SMN2 1144/4885PLA2G1B 2356/4885
US-12110311-B2 Cyclic deoxyribonucleotide compounds DPYD, TYMP, TYMS LMNA 1892/4885SMN1; SMN2 2792/4885PLA2G1B 2398/4885
US-11427550-B2 5-fluorouracil compounds DPYD, DHFR, MTHFD1 LMNA 1038/4885SMN1; SMN2 1251/4885PLA2G1B 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback